英国近期感染HIV-1者中非整合酶INSTI耐药相关突变的真实流行率及病毒学结局
研究对2015-2021年英国1106例近期感染HIV-1者进行全基因组测序,其中375人启动基于INSTI的方案。常见非整合酶突变包括Env Y61H(10%)、A539V(5.0%)、3'PPT c9053t(5.0%)和NC N8S(4.8%),均与病毒抑制时间或病毒反弹无显著关联。
要点
- 近期感染HIV-1者中非整合酶突变流行率较高,但未影响INSTI方案病毒学结局。
- Env A539V突变者更常伴随辅助INSTI突变(P = .002)。
- 该人群启动INSTI方案后24个月内中位病毒载量检测次数为4次。
核心结论
- 在近期感染HIV-1且启动INSTI方案的治疗初治者中,非整合酶突变虽流行但未显示对病毒学结局的影响。
研究设计与样本
- 2015-2021年英国近期感染HIV-1者全基因组测序,共1106例,其中375例启动INSTI方案。
- 序列与英国健康安全局HIV和艾滋病报告系统中的人口学和临床数据链接。
主要发现
- Env Y61H是最常见的非整合酶突变,占10%(33/375)。
- Env A539V、3'PPT c9053t和NC N8S的流行率分别为5.0%(16/375)、5.0%(17/375)和4.8%(16/375)。
- 单变量和多变量Cox回归未发现这些突变单独与病毒抑制时间或病毒反弹显著相关。
- Env A539V突变者中辅助INSTI突变显著更常见(P = .002)。
关键数值与推荐
- 375例启动INSTI方案者中,337例(90%)为男性,196例(52%)为B亚型,中位年龄33岁。
- 启动ART后24个月内病毒载量检测次数中位数为4次。
临床怎么用
- 对于近期感染HIV-1且启动INSTI方案的患者,非整合酶突变的存在可能不影响初始病毒学应答。
- Env A539V突变与辅助INSTI突变的关联值得进一步关注。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Integrase strand transfer inhibitors (INSTIs) are the mainstay of antiretroviral therapy (ART) globally. Virological breakthrough is uncommon but often manifests as low-level viremia, and only 50% of cases have identified drug resistance mutations in the integrase gene. Nonintegrase mutations in the Gag-nucleocapsid protein (NC), envelope glycoprotein (Env), and 3' polypurine tract (3'PPT) have been identified in vitro. METHODS: Between 2015 and 2021, human immunodeficiency virus type 1 (HIV-1) whole genome sequencing was performed on samples from people with recently acquired HIV-1 in the United Kingdom. Sequences were linked to demographic and clinical data within the UK Health Security Agency's HIV and AIDS Reporting System. The relationship between nonintegrase enzyme mutations and virological outcomes was assessed. Of 1106 participants, 375 (34%) started an INSTI-based regimen. Of these, 337 (90%) were men and 196 (52%) were living with subtype B. The median age was 33 years and number of viral loads within 24 months of starting ART was 4. RESULTS: Overall, Env Y61H (33 [10%]), A539V (16 [5.0%]), 3'PPT c9053t (17 [5.0%]), and NC N8S (16 [4.8%]) were the most prevalent nonintegrase enzyme mutations. Univariable and multivariable Cox regression did not identify significant associations between the presence of these mutations individually and time to viral suppression, or to viral blip. Interestingly, accessory INSTI mutations were found significantly more frequently in people whose virus also harbored the Env mutation A539V (P = .002). CONCLUSIONS: Several nonintegrase mutations were prevalent, but we found no evidence of an impact upon virological outcomes within treatment-naive individuals on INSTI-based regimens who had recently acquired HIV.
引用
- Kelly C, Lester JS, Bradshaw D, et al. Real-world Prevalence of Nonintegrase INSTI Resistance-Associated Mutations and Virological Outcomes in People Who Have Recently Acquired HIV-1 in the United Kingdom. J Infect Dis. 2026. PMID: 41004608. doi:10.1093/infdis/jiaf500
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。